Inovio Pharmaceuticals, Inc. (INO) · Nov 2, 2026 · Other events

INOVIO FDA approval launches VOCERYQ—but confirmatory trial remains

FDA accelerated approval — VOCERYQ approved to reduce surgery frequency in adults with RRP

INOVIO’s FDA approval of VOCERYQ turns its DNA-medicine platform into a commercial business, with launch planned in early 2027 but confirmatory data still required.

INOVIO is moving from a clinical-stage biotech built around INO-3107 into a company preparing to sell its first product. Before this filing, the FDA’s action was scheduled for October 30, 2026, and INOVIO had already been preparing commercial launch activities; its latest reported cash position was intended to fund operations through a potential launch and into late first quarter 2027. The approval materially rewrites the business story. VOCERYQ is now approved to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis, giving INOVIO a commercial product and validating its DNA-medicine platform beyond clinical development. The clinical bar was meaningful, but the evidence base is small. The approval rests on 32 treated adults, with 7 of 26 patients in the efficacy population requiring no surgical excision during the 12 months after treatment—a potentially important reduction in surgical burden, but not the same as broad, randomized commercial-stage validation. 〔0〕 The key qualification is accelerated approval, not full clinical closure. Continued approval may depend on a confirmatory study, with the FDA requiring a draft protocol by the end of 2026 and expected final-protocol alignment by mid-2027. That leaves a regulatory execution obligation attached to the launch rather than removing the development risk entirely. 〔1〕 Commercial execution now becomes the next test. INOVIO expects product availability in roughly 60 days and full field deployment in the first quarter of 2027, using Syneos Health to build medical and commercial coverage. The timing is broadly consistent with the company’s pre-filing plan, so the surprise is less the launch schedule than the fact that the company has cleared the approval gate. 〔2〕 Bottom line: This is a company-changing approval that advances INOVIO from platform promise to commercial execution. The story is materially stronger, but it now depends on launch uptake, financing discipline, and confirmatory evidence to convert accelerated approval into durable commercial status.

What to watch next

Confirmatory-study protocol due to FDA by year-end 2026

Original filing on SEC EDGAR